Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 6, 2013, Pages 530-538

  Grierson, Rebecca ^a   Meyer Rüsenberg, Birthe ^a   Kunst, Frank ^a   Berna, Marc J ^a   Richard, Gisbert ^a   Thill, Michelle ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; PROTEIN BLOOD LEVEL; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; CELL COUNT; CHEMOKINE CXCL12; CHOROIDAL NEOVASCULARIZATION; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880205085     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0013     Document Type: Article

References (54)

1. Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1419-1431, 2006
2. Brown, D.M., Kaiser, P.K., Michels, M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1432-1444, 2006.
3. Schmidt-Erfurth, U Clinical safety of ranibizumab in agerelated macular degeneration. Expert Opin. Drug Saf. 9:149-165, 2010.
4. Lalwani, G.A., Rosenfeld, P.J., Fung, A.E., et al A variabledosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am. J. Ophthalmol. 148:43-58, 2009; e41.
5. Cohen, S.Y., Dubois, L., Tadayoni, R., et al Results of oneyear's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am. J. Ophthalmol. 148:409-413, 2009.
6. Thill, M., Strunnikova, N.V., Berna, M.J., et al Late outgrowth endothelial progenitor cells in patients with agerelated macular degeneration. Invest. Ophthalmol. Vis. Sci. 49:2696-2708, 2008.
7. Espinosa-Heidmann, D.G., Reinoso, M.A., Pina, Y., Csaky, K.G., Caicedo, A., and Cousins, S.W Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularization. Exp. Eye Res. 80:369-378, 2005.
8. Espinosa-Heidmann, D.G., Caicedo, A., Hernandez, E.P., Csaky, K.G., and Cousins, S.W Bone marrow-derived progenitor cells contribute to experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44:4914-4919, 2003.
9. Sengupta, N., Caballero, S., Mames, R.N., Butler, J.M., Scott, E.W., and Grant, M.B. The role of adult bone marrowderived stem cells in choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44:4908-4913, 2003.
10. Tomita, M., Yamada, H., Adachi, Y., et al. Choroidal neovascularization is provided by bone marrow cells. Stem Cells 22:21-26, 2004.
11. Hou, H.Y., Wang, Y.S., Xu, J.F., Wang, Y.C., and Liu, J.P. The dynamic conduct of bone marrow-derived cells in the choroidal neovascularization microenvironment. Curr. Eye Res. 31:1051-1061, 2006.
12. Asahara, T., Takahashi, T., Masuda, H., et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18: 3964-3972, 1999.
13. Li, Y., Reca, R.G., Atmaca-Sonmez, P., et al. Retinal pigment epithelium damage enhances expression of chemoattractants and migration of bone marrow-derived stem cells. Invest. Ophthalmol. Vis. Sci. 47:1646-1652, 2006.
14. Murayama, T., Tepper, O.M., Silver, M., et al. Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo. Exp. Hematol. 30:967-972, 2002.
15. Hattori, K., Dias, S., Heissig, B., et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 193:1005-1014, 2001.
16. Gehling, U.M., Ergun, S., Schumacher, U., et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95:3106-3112, 2000.
17. Aiello, L.P., Northrup, J.M., Keyt, B.A., Takagi, H., and Iwamoto, M.A. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch. Ophthalmol. 113:1538- 1544, 1995.
18. Adamis, A.P., Shima, D.T., Yeo, K.T., et al. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem. Biophys. Res. Commun. 193:631-638, 1993.
19. Funk, M., Karl, D., Georgopoulos, M., et al. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 116:2393-2399, 2009.
20. Campochiaro, P.A., Choy, D.F., Do, D.V., et al. Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology 116:2158-2164, 2009.
21. Aiello, L.P., Avery, R.L., Arrigg, P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabeticretinopathy and other retinal disorders. N. Engl. J. Med. 331: 1480-1487, 1994.
22. Funk, M., Kriechbaum, K., Prager, F., et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest. Ophthalmol. Vis. Sci. 50:1025-1032, 2009.
23. Lip, P.L., Belgore, F., Blann, A.D., Hope-Ross, M.W., Gibson, J.M., and Lip, G.Y. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Invest. Ophthalmol. Vis. Sci. 41:2115-2119, 2000.
24. Lip, P.L., Blann, A.D., Hope-Ross, M., Gibson, J.M., and Lip, G.Y. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology 108:705-710, 2001.
25. Tsai, D.C., Charng, M.J., Lee, F.L., Hsu, W.M., and Chen, S.J. Different plasma levels of vascular endothelial growth factor and nitric oxide between patients with choroidal and retinal neovascularization. Ophthalmologica 220:246-251, 2006.
26. Petit, I., Jin, D., and Rafii, S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol. 28:299-307, 2007.
27. De Falco, E., Porcelli, D., Torella, A.R., et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 104: 3472-3482, 2004.
28. Murukesh, N., Dive, C., and Jayson, G.C. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br. J. Cancer 102:8-18, 2010.
29. Lin, Y., Weisdorf, D.J., Solovey, A., and Hebbel, R.P. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 105:71-77, 2000.
30. Stevens, T.S., Bressler, N.M., Maguire, M.G., et al. Occult choroidal neovascularization in age-related macular degeneration. A natural history study. Arch. Ophthalmol. 115:345- 350, 1997.
31. Michels, S., and Schmidt-Erfurth, U. Sequence of early vascular events after photodynamic therapy. Invest. Ophthalmol. Vis. Sci. 44:2147-2154, 2003.
32. Machalinska, A., Paczkowska, E., Pabin, T., Safranow, K., Karczewicz, D., and Machalinski, B. Influence of ranibizumab on vascular endothelial growth factor plasma level and endothelial progenitor cell mobilization in age-related macular degeneration patients: safety of intravitreal treatment for vascular homeostasis. J. Ocul. Pharmacol. Ther. 27:471- 475, 2011.
33. Moore, M.A., Hattori, K., Heissig, B., et al. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann. N. Y. Acad. Sci. 938:36-45, 2001; discussion 45-37.
34. Hattori, K., Heissig, B., Tashiro, K., et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 97:3354-3360, 2001.
35. Jain, R.K., Duda, D.G., Willett, C.G., et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6:327-338, 2009.
36. Yoder, M.C., and Ingram, D.A. The definition of EPCs and other bone marrow cells contributing to neoangiogenesis and tumor growth: is there common ground for understanding the roles of numerous marrow-derived cells in the neoangiogenic process? Biochim. Biophys. Acta 1796:50-54, 2009.
37. Yodoi, Y., Sasahara, M., Kameda, T., Yoshimura, N., and Otani, A. Circulating hematopoietic stem cells in patients with neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 48:5464-5472, 2007.
38. Ahn, J.K., and Moon, H.J. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration. Am. J. Ophthalmol. 148:718-724, 2009; e711.
39. Roh, M.I., Lim, S.J., Ahn, J.M., Lim, J.B., and Kwon, O.W. Concentration of cytokines in age-related macular degeneration after consecutive intravitreal bevacizumab injection. Graefes Arch. Clin. Exp. Ophthalmol. 248:635-640, 2010.
40. Chan, W.M., Lai, T.Y., Chan, K.P., et al. Changes in aqueous vascular endothelial growth factor and pigment epithelialderived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to agerelated macular degeneration or pathologic myopia. Retina 28:1308-1313, 2008.
41. Lai, T.Y., Liu, D.T., Chan, K.P., Luk, F.O., Pang, C.P., and Lam, D.S. Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial. Retina 29:1218-1226, 2009.
42. Carneiro, A.M., Costa, R., Falcao, M.S., et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol. 90:e25-30, 2011.
43. Bakri, S.J., Snyder, M.R., Reid, J.M., Pulido, J.S., Ezzat, M.K., and Singh, R.J. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179-2182, 2007.
44. Gaudreault, J., Fei, D., Beyer, J.C., et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 27:1260-1266, 2007.
45. Gaudreault, J., Fei, D., Rusit, J., Suboc, P., and Shiu, V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci. 46:726-733, 2005.
46. Funatsu, H., Yamashita, H., Ikeda, T., Nakanishi, Y., Kitano, S., and Hori, S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am. J. Ophthalmol. 133:537-543, 2002.
47. Noma, H., Funatsu, H., Yamasaki, M., et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am. J. Ophthalmol. 140:256-261, 2005.
48. Siegel, A.B., Cohen, E.I., Ocean, A., et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol. 26: 2992-2998, 2008.
49. Fischer, C., Jonckx, B., Mazzone, M., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131:463-475, 2007.
50. Roodhart, J.M., Langenberg, M.H., Witteveen, E., and Voest, E.E. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr. Clin. Pharmacol. 3:132-143, 2008.
51. Roh, M.I., Kim, H.S., Song, J.H., Lim, J.B., Koh, H.J., and Kwon, O.W. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with AMD after bevacizumab treatment. Retina 29:523-529, 2009.
52. Guerin, E., Sheridan, C., Assheton, D., et al. SDF1-alpha is associated with VEGFR-2 in human choroidal neovascularisation. Microvasc. Res. 75:302-307, 2008.
53. Arimura, N., Otsuka, H., Yamakiri, K., et al. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology 116:921-926, 2009.
54. Zagzag, D., Esencay, M., Mendez, O., et al. Hypoxia- and vascular endothelial growth factor-induced stromal cellderived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am. J. Pathol. 173:545-560, 2008